Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Peritoneal Dialysis | Research

Analysis of factors influencing vascular calcification in peritoneal dialysis patients and their impact on long-term prognosis

Authors: Qianying Cao, Yanan Shi, Xiaohui Liu, Fan Yang, Xiangnan Li, Zhongxin Li

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

This study aims to investigate the influencing factors of vascular calcification in peritoneal dialysis (PD) patients and its relationship with long-term prognosis.

Methods

This retrospective cohort study included chronic kidney disease patients undergoing peritoneal dialysis at the Peritoneal Dialysis Center of Beijing Luhu Hospital, Capital Medical University, from January 2019 to March 2019. Demographic and clinical laboratory data, including serum sclerostin (SOST), calcium (Ca), phosphate (P), serum albumin (ALB), and intact parathyroid hormone (iPTH) levels, were collected. Abdominal aortic calcification (AAC) was assessed using abdominal lateral X-ray examination to determine the occurrence of vascular calcification, and patients were divided into the AAC group and Non-AAC group based on the results.

Results

A total of 91 patients were included in the study. The AAC group consisted of 46 patients, while the Non-AAC group consisted of 45 patients. The AAC group had significantly older patients compared to the non-AAC group (P < 0.001) and longer dialysis time (P = 0.004). Multivariable logistic regression analysis indicated that risk factors for vascular calcification in PD patients included dialysis time, diabetes, hypertension, and SOST. Kaplan–Meier survival analysis showed that the AAC group had a significantly higher mortality rate than the non-AAC group (χ2 = 35.993, P < 0.001). Multivariable Cox regression analysis revealed that dialysis time, diabetes and AAC were risk factors for all-cause mortality in peritoneal dialysis patients.

Conclusion

Longer dialysis time, comorbid diabetes, comorbid hypertension, and SOST are risk factors for vascular calcification in PD patients. Additionally, AAC, longer dialysis time, and comorbid diabetes are associated with increased risk of all-cause mortality in peritoneal dialysis patients.
Literature
1.
go back to reference Yao Z, Wang C, Zhang Q, Ma S, Gui B, Duan C. Prevalence of abdominal artery calcification in dialysis patients with end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(11):2061–9.CrossRefPubMed Yao Z, Wang C, Zhang Q, Ma S, Gui B, Duan C. Prevalence of abdominal artery calcification in dialysis patients with end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(11):2061–9.CrossRefPubMed
2.
go back to reference Dilsizian V, Gewirtz H, Marwick TH, et al. Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease. JACC Cardiovasc Imaging. 2021;14(3):669–82.CrossRefPubMed Dilsizian V, Gewirtz H, Marwick TH, et al. Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease. JACC Cardiovasc Imaging. 2021;14(3):669–82.CrossRefPubMed
3.
go back to reference Sag AA, Covic A, London G, et al. Clinical imaging of vascular disease in chronic kidney disease. Int Urol Nephrol. 2016;48(6):827–37.CrossRefPubMed Sag AA, Covic A, London G, et al. Clinical imaging of vascular disease in chronic kidney disease. Int Urol Nephrol. 2016;48(6):827–37.CrossRefPubMed
4.
go back to reference Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int. 2006;70(9):1623–8.CrossRefPubMed Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int. 2006;70(9):1623–8.CrossRefPubMed
5.
go back to reference Takayama Y, Yasuda Y, Suzuki S, et al. Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients. Heart Vessels. 2016;31(7):1030–7.CrossRefPubMed Takayama Y, Yasuda Y, Suzuki S, et al. Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients. Heart Vessels. 2016;31(7):1030–7.CrossRefPubMed
6.
go back to reference Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.CrossRefPubMed Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.CrossRefPubMed
7.
go back to reference Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72.CrossRefPubMedPubMedCentral Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72.CrossRefPubMedPubMedCentral
8.
go back to reference Verbeke F, Van Biesen W, Honkanen E, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am SocNephrol. 2011;6(1):153–9.CrossRef Verbeke F, Van Biesen W, Honkanen E, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am SocNephrol. 2011;6(1):153–9.CrossRef
9.
go back to reference Chen HC, Chou CY, Lin HJ, Huang CC, Chang CT. Abdominal aortic calcification score predicts the occurrence of coronary artery disease in middle-aged peritoneal dialysis patients. Nephrology (Carlton). 2019;24(3):336–40.CrossRefPubMed Chen HC, Chou CY, Lin HJ, Huang CC, Chang CT. Abdominal aortic calcification score predicts the occurrence of coronary artery disease in middle-aged peritoneal dialysis patients. Nephrology (Carlton). 2019;24(3):336–40.CrossRefPubMed
10.
11.
go back to reference Román-García P, Carrillo-López N, Fernández-Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-Andía JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46(1):121–8.CrossRefPubMed Román-García P, Carrillo-López N, Fernández-Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-Andía JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46(1):121–8.CrossRefPubMed
12.
go back to reference De Maré A, Maudsley S, Azmi A, et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel). 2019;11(7):428.CrossRefPubMed De Maré A, Maudsley S, Azmi A, et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel). 2019;11(7):428.CrossRefPubMed
13.
go back to reference Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. DiabVasc Dis Res. 2018;15(2):99–105.CrossRef Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. DiabVasc Dis Res. 2018;15(2):99–105.CrossRef
14.
go back to reference Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–45.CrossRefPubMed Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–45.CrossRefPubMed
15.
go back to reference Li M, Zhou H, Yang M, Xing C. Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol. 2019;51(2):311–23.CrossRefPubMed Li M, Zhou H, Yang M, Xing C. Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol. 2019;51(2):311–23.CrossRefPubMed
16.
go back to reference Sun X, Yang K, Wang C, et al. Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers. Int J Med Sci. 2015;12(3):270–9.CrossRefPubMedPubMedCentral Sun X, Yang K, Wang C, et al. Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers. Int J Med Sci. 2015;12(3):270–9.CrossRefPubMedPubMedCentral
17.
go back to reference Williams MJ, White SC, Joseph Z, Hruska KA. Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone-Vascular paradox, a therapeutic target, and a biomarker. Front Physiol. 2023;14:1120308.CrossRefPubMedPubMedCentral Williams MJ, White SC, Joseph Z, Hruska KA. Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone-Vascular paradox, a therapeutic target, and a biomarker. Front Physiol. 2023;14:1120308.CrossRefPubMedPubMedCentral
18.
go back to reference Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819–23.CrossRefPubMedPubMedCentral Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819–23.CrossRefPubMedPubMedCentral
19.
go back to reference Brandenburg VM, D’Haese P, Deck A, et al. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol. 2016;31(2):195–206.CrossRefPubMed Brandenburg VM, D’Haese P, Deck A, et al. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol. 2016;31(2):195–206.CrossRefPubMed
20.
go back to reference Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248–55.CrossRefPubMed Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248–55.CrossRefPubMed
21.
go back to reference Novo-Rodríguez C, García-Fontana B, Luna-Del Castillo JD, et al. Circulating levels of sclerostinare associated with cardiovascular mortality. PLoS ONE. 2018;13(6):e0199504.CrossRefPubMedPubMedCentral Novo-Rodríguez C, García-Fontana B, Luna-Del Castillo JD, et al. Circulating levels of sclerostinare associated with cardiovascular mortality. PLoS ONE. 2018;13(6):e0199504.CrossRefPubMedPubMedCentral
22.
go back to reference Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE. 2011;6(5):e19595.CrossRefPubMedPubMedCentral Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE. 2011;6(5):e19595.CrossRefPubMedPubMedCentral
23.
go back to reference Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013;22(3):317–25.PubMed Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013;22(3):317–25.PubMed
24.
go back to reference Morales-Santana S, García-Fontana B, García-Martín A, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013;36(6):1667–74.CrossRefPubMedPubMedCentral Morales-Santana S, García-Fontana B, García-Martín A, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013;36(6):1667–74.CrossRefPubMedPubMedCentral
25.
go back to reference Balcı M, Kırkpantur A, Turkvatan A, Mandıroglu S, Ozturk E, Afsar B. Sclerostin as a new key player in arteriovenous fistula calcification. Herz. 2015;40(2):289–97.CrossRefPubMed Balcı M, Kırkpantur A, Turkvatan A, Mandıroglu S, Ozturk E, Afsar B. Sclerostin as a new key player in arteriovenous fistula calcification. Herz. 2015;40(2):289–97.CrossRefPubMed
26.
go back to reference Chen A, Sun Y, Cui J, et al. Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis. BMC Nephrol. 2018;19(1):264.CrossRefPubMedPubMedCentral Chen A, Sun Y, Cui J, et al. Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis. BMC Nephrol. 2018;19(1):264.CrossRefPubMedPubMedCentral
27.
go back to reference Medicine AA, EC. Retracted: The Correlation between Serum Sclerostin Level and Arterial Stiffness in Peritoneal Dialysis Patients. Evid Based Complement Alternat Med. 2023;2023:9807476. Medicine AA, EC. Retracted: The Correlation between Serum Sclerostin Level and Arterial Stiffness in Peritoneal Dialysis Patients. Evid Based Complement Alternat Med. 2023;2023:9807476.
28.
go back to reference Qureshi AR, Olauson H, Witasp A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88(6):1356–64.CrossRefPubMed Qureshi AR, Olauson H, Witasp A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88(6):1356–64.CrossRefPubMed
29.
go back to reference Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology (Carlton). 2017;22(4):286–92.CrossRefPubMed Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology (Carlton). 2017;22(4):286–92.CrossRefPubMed
30.
go back to reference Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–56.CrossRefPubMed Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–56.CrossRefPubMed
31.
go back to reference Noordzij M, Cranenburg EM, Engelsman LF, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26(5):1662–9.CrossRefPubMed Noordzij M, Cranenburg EM, Engelsman LF, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26(5):1662–9.CrossRefPubMed
32.
go back to reference Lee MJ, Shin DH, Kim SJ, et al. Progression of aortic arch calcification over 1 year is an independent predictor of mortality in incident peritoneal dialysis patients. PLoS ONE. 2012;7(11):e48793.CrossRefPubMedPubMedCentral Lee MJ, Shin DH, Kim SJ, et al. Progression of aortic arch calcification over 1 year is an independent predictor of mortality in incident peritoneal dialysis patients. PLoS ONE. 2012;7(11):e48793.CrossRefPubMedPubMedCentral
33.
go back to reference Kurita N, Hosokawa N, Nomura S, Maeda Y, Uchihara H, Fukuhara S. A simple four-grade score for aortic arch calcification by posteroanterior chest X-ray is associated with cardiovascular disease in haemodialysis patients. Nephrol Dial Transplant. 2011;26(5):1747–8.CrossRefPubMed Kurita N, Hosokawa N, Nomura S, Maeda Y, Uchihara H, Fukuhara S. A simple four-grade score for aortic arch calcification by posteroanterior chest X-ray is associated with cardiovascular disease in haemodialysis patients. Nephrol Dial Transplant. 2011;26(5):1747–8.CrossRefPubMed
34.
go back to reference Niu Q, Zhao H, Wu B, et al. Abdominal aortic calcification is superior to other arteries calcification in predicting the mortality in peritoneal dialysis patients - a 8 years cohort study. BMC Nephrol. 2019;20(1):439.CrossRefPubMedPubMedCentral Niu Q, Zhao H, Wu B, et al. Abdominal aortic calcification is superior to other arteries calcification in predicting the mortality in peritoneal dialysis patients - a 8 years cohort study. BMC Nephrol. 2019;20(1):439.CrossRefPubMedPubMedCentral
35.
36.
go back to reference Kanbay M, Solak Y, Siriopol D, et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):2029–42.CrossRefPubMed Kanbay M, Solak Y, Siriopol D, et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):2029–42.CrossRefPubMed
Metadata
Title
Analysis of factors influencing vascular calcification in peritoneal dialysis patients and their impact on long-term prognosis
Authors
Qianying Cao
Yanan Shi
Xiaohui Liu
Fan Yang
Xiangnan Li
Zhongxin Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03582-2

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.